SCHEMBL1816682

SCHEMBL1816682

NC(=O)OC(=S)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
TSHR P16473 3/20 0.50
CYP3A4 P08684 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP2C19 P33261 2/20 0.50
POLB P06746 2/20 0.50
PARP1 P09874 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 3/20 0.48
CES1 P23141 3/20 0.43
KMT2A Q03164 2/20 0.43
F2 P00734 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL489956 0.81 MAPT (0.44) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL29278243 0.79 ALDH1A1 (0.46) MAPTTDP1POLBALDH1A1CES1
SCHEMBL11394434 0.78 ELANE (0.47) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL28399559 0.78 CES1 (0.43) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL29234727 0.78 CA2 (0.50) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL7096723 0.78 TDP1 (0.43) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL118930 0.77 LMNA (0.58) MAPTTSHRCYP3A4TDP1CYP2C19
Benzene SCHEMBL28096283 0.77 LMNA (0.58) MAPTTSHRCYP3A4TDP1CYP2C19
SCHEMBL29234728 0.77 MAPT (0.41) MAPTTSHRCYP3A4TDP1CYP2C19
Water SCHEMBL27554784 0.76 LMNA (0.56) MAPTTSHRCYP3A4TDP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912653-B1 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-01-01 EP disclosed
EP-1765805-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-11-20 EP disclosed
EP-1861399-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-12-14 EP disclosed
US-8039460-B2 CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine MERCK SHARP & DOHME CORP. (US) 2011-10-18 US disclosed
US-7994325-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK SHARP & DOHME CORP. (US) 2011-08-09 US disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
EP-1856100-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2010-05-05 EP disclosed
US-7632832-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2009-12-15 US disclosed
EP-1765805-A4 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-08-26 EP disclosed
US-20090105228-A1 Heterocyclic benzodiazepine cgrp receptor antagonists MERCK SHARP & DOHME LLC 2009-04-23 US disclosed
EP-1861399-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-12-05 EP disclosed
EP-1856100-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-11-21 EP disclosed
EP-1802637-A1 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-07-04 EP disclosed
EP-1765805-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-03-28 EP disclosed
WO-2007016087-A2 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-02-08 WO disclosed
WO-2006099268-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-09-21 WO disclosed
WO-2006078554-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-07-27 WO disclosed
WO-2006044504-A1 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-04-27 WO disclosed
WO-2005072308-A9 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2006-02-02 WO disclosed
WO-2005072308-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105228-A1 Heterocyclic benzodiazepine cgrp receptor antagonists BDKRB2, BDKRB1, CCKBR MAPT 3753/4885TSHR 377/4885CYP3A4 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.